Long-term Survival After Non-small Cell Lung Cancer Surgery: Development and Validation of a Prognostic Model with a Preoperative and Postoperative Mode
Overview
Authors
Affiliations
Objective: At present, there is no prognostic model that is specific for prediction of survival after non-small cell lung cancer surgery. We aimed to develop a prognostic model that can be used to estimate the postoperative survival of individual patients.
Methods: A total of 766 patients underwent resection for primary non-small cell lung cancer. Comorbid conditions were scaled according to the Charlson comorbidity index (CCI). Cox proportional hazard analyses were used to determine risk factors for survival. A prognostic model for survival with a preoperative and postoperative mode was established. Performance of the prognostic model, the CCI, and pathologic tumor stage were quantified by a concordance statistic to indicate discriminative ability.
Results: The factors associated with an impaired survival were male sex, age, chronic obstructive pulmonary disease, congestive heart failure, any prior tumor, moderate-to-severe renal disease (preoperative and postoperative mode), clinical tumor stage (preoperative mode), type of resection, and pathologic tumor stage (postoperative mode). The discriminative performance was poor for the CCI (c = 0.55), better for pathologic tumor stage (c = 0.60) and for the preoperative mode (c = 0.61), and best for the postoperative mode (c = 0.65). The discriminative performance of the postoperative mode was better than the discriminative performance of the CCI (P < .0001), the preoperative mode (P < .0002), and pathologic tumor stage (P < .0001). The discriminative performance of the preoperative mode was better than the discriminative performance of the CCI (P < .0001) and similar (P = .90) to a model that only included pathologic tumor stage.
Conclusions: The prognostic model, particularly the postoperative mode, successfully estimates long-term survival of individual patients and could help clinicians in clinical decision-making and treatment tailoring.
Wang W, Zhou J Cancer Control. 2023; 30:10732748231197973.
PMID: 37703536 PMC: 10501081. DOI: 10.1177/10732748231197973.
Zeng Y, Liu J, Wan M, Li Q, Liu H, Cui F J Thorac Dis. 2023; 15(1):42-53.
PMID: 36794137 PMC: 9922593. DOI: 10.21037/jtd-22-772.
Xu B, Ye Z, Zhu L, Xu C, Lu M, Wang Q Front Med (Lausanne). 2023; 9:972879.
PMID: 36619647 PMC: 9811385. DOI: 10.3389/fmed.2022.972879.
Jiang Y, Chen S, Wu Y, Qu Y, Jia L, Xu Q Cancer Cell Int. 2022; 22(1):300.
PMID: 36184588 PMC: 9528074. DOI: 10.1186/s12935-022-02725-5.
Shang X, Yu H, Lin J, Li Z, Zhao C, Sun J J Oncol. 2020; 2020:7863984.
PMID: 32565807 PMC: 7256774. DOI: 10.1155/2020/7863984.